thereby, interferes with T cell activation. 2 We have previously reported that FK506, when combined with the antiSeveral steroid receptor-associated heat shock proteins metabolite methotrexate (MTX), provides strong immunocan bind to FK506 as immunophilins. This has led to suppression, and may effectively prevent graft-versus-host speculation that the steroid receptor and immunophilin disease (GVHD) and induce long-term survival in a canine signal transduction pathways are functionally intermodel of unrelated marrow grafts. 3 The MTX/FK506 related. Indeed, in vitro work showed that FK506 treatregimen is now being explored in human marrow transment of intact L929 cells which were stably transfected plants. [4][5][6] A major problem that limits the efficacy of with various reporter plasmids resulted in a potentiimmunosuppressive drugs both in dogs and in humans has ation of glucocorticoid hormone-induced glucocorticoid been their associated toxicities. Reductions in drug dosages receptor-mediated gene transcription. These findings that have been brought about by intolerable drug toxicities have raised the possibility of additive or synergistic observed clinically can result in an increased incidence of immunosuppressive effects of FK506 and glucocortico-GVHD. 4 Similarly, an attempt to reduce FK506 toxicities ids. We tested this hypothesis in a canine model of in dogs by dose reduction led to impaired GVHD preven-GVHD prevention. Two groups of dogs were given 9.2 tion. 7 A way around the problem of toxicity of a given drug Gy total body irradiation followed by hematopoietic is to combine several immunosuppressive agents, as is done grafts from unrelated DLA-nonidentical donors. Among in cancer chemotherapy. Indeed, certain drug combinations the first group of four recipients which were given have proved to be synergistic with respect to GVHD pre-FK506 and glucocorticoids, one rejected the graft, while vention, eg MTX/CSP and MTX/FK506. three developed acute GVHD and died from associated Corticosteroids have also been added to other immunocomplications between days 14 and 34. In the second suppressive agents for GVHD prevention, although results group of nine recipients which were given FK506, glucohave been equivocal. 4,5,[8][9][10][11][12][13] Yet, corticosteroids have been corticoids and methotrexate (MTX), only one dog successfully used to treat acute and chronic GVHD.
2,6,14-17 became a long-term survivor while eight dogs died
Recent work has shown that the steroid receptor-associated between days 21-114 with GVHD (n = 5) or FK506-heat shock protein, Hsp56, belongs to the FK506 family of associated toxicities (n = 3). Thus, addition of glucocorimmunophilin proteins. [18] [19] [20] [21] The ability of Hsp56 to bind ticoids to FK506 or FK506/MTX showed neither syner-FK506 has led to speculation that steroid receptor and gistic nor additive effects with respect to GVHD prevenimmunophilin signal transduction pathways are function in this model, and no survival advantages were seen tionally interrelated. [22] [23] [24] Indeed, in vitro studies showed compared to previously reported results with FK506 that FK506 treatment of mouse L929 cells which were alone or FK506 and MTX in combination, respectively.
stably transfected with various reporter plasmids resulted Keywords: FK506; MTX; steroids; GVHD in a potentiation of glucocorticoid hormone induced glucocorticoid receptor-mediated gene transcription. 25 These in vitro findings have raised the possibility of additive or even Immunophilins are proteins capable of binding immunosupsynergistic immunosuppressive effects when FK506 is pressive agents. Two distinct classes of immunophilins combined with corticosteroids. The current study tested this have been identified. The cyclophilin family binds cycloconcept in two groups of dogs given 9.2 Gy total body sporine (CSP), whereas FK506-binding protein (FKBP) irradiation (TBI) and allogeneic hematopoietic grafts from binds tacrolimus (FK506) and rapamycin.
1 FK506 binds to DLA-nonidentical unrelated donors. One group of dogs was FKBP12 and associates with calcineurin, thereby blocking given glucocorticoids combined with FK506 alone and the its phosphatase activity. This prevents interleukin-2 (IL-2) other was administered glucocorticoids in addition to transcription mediated by nuclear factor-AT (NF-AT) and, MTX/FK506. results were compared to those in concurrent and historical grees for at least five generations, and were chosen on the control dogs which were either given no post-grafting basis of mismatching for dog histocompatibility antigen immunosuppression, MTX/FK506 as currently adminis-DLA-DB identified by direct gene sequencing. 26, 27 tered or FK506 alone, administered at twice the current dose on days 0-8, respectively.
Materials and methods

Marrow transplant, TBI, supportive care, engraftment, GVHD Statistical methods
Donor marrow cells were aspirated under general anesExact binomial confidence intervals for the proportion of thesia through needles inserted into humeri and femora.
dogs surviving Ͼ150 days after transplant were calculated Recipients were administered TBI at a dose of 920 cGy for the current study groups, as well as the historical control delivered at 7 cGy/min from two opposing cobalt-60 groups. Two-sample testing for a difference in the prosources. 28 Within 4 h of TBI, marrow cells were infused portions of dogs surviving was done using a Monte Carlo intravenously (i.v.) at doses of 0.7-6.0 (median 4.0, mean simulation method appropriate for small sample sizes. 3.5) × 10 8 nucleated cells/kg. The day of marrow grafting was designated as 'day 0'. In addition, on days 1 and 2 recipients were given i.v. infusions of 4.7-21.1 (median 12, Results mean 12.2) × 10 8 peripheral blood buffy coat cells/kg from their marrow donors and which are necessary for consistent Table 1 shows the results. Four dogs in group 1 were given engraftment in this model. 29, 30 The number of donor buffy FK506 plus corticosteroids. One failed to engraft and died coat cells infused does not have a direct influence on the with marrow aplasia. Three engrafted, developed severe manifestation and severity of GVHD in this setting. 29, 30 GVHD, and were euthanized between days 14 and 34 Marrow engraftment was assessed in each recipient by because of deteriorating clinical condition. documentation of cells with donor (CA) n repeat polymorAll nine dogs in group 2 given MTX/FK506/ phisms in specimens from peripheral blood and marrow, 31 corticosteroids engrafted. Eight developed clinically sigby sustained increases in granulocyte and platelet counts nificant acute GVHD and one did not. The dog without after post-irradiation nadir, by histologic features of the GVHD died of intussusception of the small bowel, a commarrow from biopsy or autopsy specimens, and by the plication that was related to FK506 gut toxicity. Of the development of GVHD. The effectiveness of GVHD preeight dogs with GVHD, all but one died or were euthanized vention is measured by the survival of recipients after transbetween 21 and 114 days because of progressively worsenplant and clinical signs and/or histological evidence of ing clinical condition. One of the eight survived with per-GVHD. Clinical signs of GVHD included severe diarrhea, sisting three system GVHD and was euthanized at the conconjunctivitis, erythroderma, elevated liver enzymes and clusion of the study on day 203 (dog E075). jaundice. Complete autopsies were done on all dogs that Table 2 summarizes results for current study groups and died. Histological examination included marrow, lymph for previously published controls. Median survival time for nodes, skin, liver, small bowel, colon and lungs.
dogs given FK506/corticosteroids was 19 days compared with 11 days for controls not given post-transplant immunosuppression, but no long-term survival was achi-GVHD prevention eved. This result was similar to that previously described for FK506 alone, 3 although the dose of FK506 in the pre-FK506 was provided by Fujisawa USA, (Deerfield, IL, USA) either as a 20% FK506 powder blend given orally vious study was higher during the first 8 days after transplant than in the current study. The results in dogs given in encapsulated form or as an intramuscular (i.m.) formulation that consisted of micronized FK506 in mannitol and MTX/FK506/corticosteroids were not statistically different MTX/CSP 12 for prevention of GVHD. However, almost all studies have been single-arm, uncontrolled trials and, thus, no firm conclusions could be drawn regarding any benefit derived from corticosteroids. One study evaluated corticosDiscussion teroids in a randomized prospective manner in patients given MTX/CSP GVHD prophylaxis. 14 That study failed While corticosteroids have a well-established place in the treatment of acute and chronic GVHD, their role in GVHD to show a reduction in incidence of acute GVHD in patients given corticosteroids and, furthermore, corticosteroidprevention is as yet less clear. Corticosteroids have been prophylaxis. Yet another prospective randomized study
